Jodapa 5mg Tablet contains Dapagliflozin 5mg, an oral antihyperglycemic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Dapagliflozin acts by inhibiting SGLT2 proteins in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering plasma glucose levels. This mechanism is independent of insulin secretion, which makes it effective in various stages of type 2 diabetes. Jodapa 5mg may be used as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. Clinical studies have demonstrated its efficacy in reducing HbA1c, fasting plasma glucose, and body weight, with additional benefits on blood pressure. Common adverse effects include urinary tract infections, genital mycotic infections, and increased urination. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to dapagliflozin. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Jodapa 5mg should be prescribed under medical supervision with appropriate lifestyle modifications for optimal diabetes management.